← Leaderboards
Rachel Dania Melamed
University Of Chicago
$1,598,133
Attributed
$1,598,133
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $367K · FY2017–25$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,598,133 · 2
By mechanism
R35$1,097,840 · 1
K01$500,293 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Nancy J. Cox$31,978,299
- Matthew Michael Churpek$8,108,899
- Mary Ann McBurnie$16,690,723
- Alicia K Matthews$13,559,974
- Sarah Cobey$9,898,587
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposInnovationPharmaceutical PreparationsMalignant NeoplasmsExperimental StudyFutureHealth DataMiningPreventSide EffectAutomobile DrivingCancerousCancer PreventionCancer TherapyClinical CareAreaClinical DataCancer Cell LineCessation Of LifeCell PhysiologyChicagoClinicCancer CellAntineoplastic Agents
Grant awards (8)
Integrating genetics and health data to discover common drug effects on cancer and Alzheimer's disease$365,947
R35 · FY2025 · GM · contact PI
Integrating genetics and health data to discover common drug effects on cancer and Alzheimer's disease$366,951
R35 · FY2024 · GM · contact PI
Integrating genetics and health data to discover common drug effects on cancer and Alzheimer's disease$364,942
R35 · FY2023 · GM · contact PI
Using clinical data to identify FDA-approved drugs for cancer prevention and therapeutic repurposing$125,433
K01 · FY2020 · ES · contact PI
Using clinical data to identify FDA-approved drugs for cancer prevention and therapeutic repurposing$1
K01 · FY2020 · ES · contact PI
Using clinical data to identify FDA-approved drugs for cancer prevention and therapeutic repurposing$124,953
K01 · FY2019 · ES · contact PI
Using clinical data to identify FDA-approved drugs for cancer prevention and therapeutic repurposing$124,953
K01 · FY2018 · ES · contact PI
Using clinical data to identify FDA-approved drugs for cancer prevention and therapeutic repurposing$124,953
K01 · FY2017 · ES · contact PI